Biological role of α-fetoprotein in cancer: Prospects for anticancer therapy

Expert Review of Anticancer Therapy

Volumn 2, Issue 6, 2002, Pages 709-735

  Mizejewski, Gerald J ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

Anticancer drug cancer; Fetal protein; Growth regulation; Oncofetal protein; Radioimaging; Receptor; Tumor therapy

Indexed keywords

ALPHA FETOPROTEIN; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BLEOMYCIN A5; CANCER VACCINE; CARRIER PROTEIN; CARUBICIN; CELL SURFACE RECEPTOR; CHLORAMBUCIL; CISPLATIN; CYTOTOXIC AGENT; DAUNORUBICIN; DIOXIN; DOXORUBICIN; ESTRADIOL; FETOPROTEIN; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHTHALOCYANINE DERIVATIVE; PROTEIN ANTIBODY; TUMOR MARKER; UNINDEXED DRUG; ALPHA FETOPROTEIN RECEPTOR, HUMAN; ALPHA-FETOPROTEIN RECEPTOR, HUMAN; BIOLOGICAL RESPONSE MODIFIER; BLOCKING ANTIBODY; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

AMINO ACID SEQUENCE; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; GENE THERAPY; GROWTH REGULATION; HUMAN; MOLECULAR CLONING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; VACCINATION; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; SCINTISCANNING;

ALPHA-FETOPROTEINS; ANIMALS; ANTIBODIES, BLOCKING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; GTP-BINDING PROTEINS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0036902921     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.6.709     Document Type: Review

References (246)

1. Mizejewski GJ. α-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. Proc. Soc. Exptl Biol. Med 215, 333-362, (1997).
2. Brock DJH, Sutcliffe RG. α-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 2, 194-197 (1972).
3. Leek AE, Ruoss CF, Kitau MJ, Chard T. Raised AF in maternal serum with anencephalic pregnancy. Lancet 2, 385-386 (1973).
4. Crandall BF. α-fetoprotein: a review. CRC Crit. Rev. Clin. Lab. Sci. 15, 127-185 (1981).
5. Smith CJP, Kelleher PC. α-fetoprotein molecular heterogeneity: physiologic correlation with normal growth, carcinogenesis and tumor growth. Biochim. Biophys. Acta 605, 1-32 (1980).
6. Uriel J. The physiological role of α-fetoprotein in cell growth and differentiation. J Nucl. Med Allied Sci. 33, 12-17 (1989).
7. Sharieff S, Burney IA, Salam A, Siddiqui T. Lack of correlation between α-fetoprotein and tumor size in hepatocellular carcinoma. J. Pakistan Med. Assoc. 51, 123-124 (2001).
8. Mizejewski GJ. New insights into AFP structure and function: potential biomedical applications. In: α-fetoprotein and Congenital Disorders. Mizejewski GJ, Porter IH (Eds) Orlando, OR, USA, 5-34, (1985).
9. Nunez EA. Biological role of α-fetoprotein in the endocrinological field: data and hypotheses. Tumor Biol. 15, 63-72 (1994).
10. Mizejewski GJ. The phylogeny of α-fetoprotein in vertebrates. Survey of biochemical and physiological data Crit. Prev. Eukaryot. Gene Expr. 5, 281-316 (1995).
11. Deutsch HF. Chemistry and biology of α-fetoprotein. Adv. Cancer Res. 56, 253-312 (1991).
12. Mizejewski GJ. α fetoprotein structure and function: relevance to isoform, epitopes and conformation variants. Expt. Biol. Med. 226, 377-408, (2001).
13. Bergstrand CG, Czar B. Paper electrophoretic study of human fetal serum proteins with demonstration of a new protein fraction. Scand J. Clin. Lab Invest. 9, 277-281 (1957).
14. Abelev GI, Perova, SD, Khramkova NI, Postnikova EA, Irlin IS. Prodution of embryonal α-globulin by transplantable mouse hepatoma. Transplantation 1, 174-178 (1963).
15. Tatarinov YS. Content of embryo-specific α-globulin in the blood serum of the human fetus, newborn and adult man in primary cancer of the liver. Vop Khim SSR 11, 20-24 (1965).
16. Masopust J, Kotal L. Fetoprotein: immunochemical behavior of a autonomous fetal component in sera from human fetuses. Ann. Paediat. Basel. 204, 138-140, (1965).
17. Gitlin D, Boesman M. Serum AFP, albumin and γ-G-globulin in the human conceptus. J. Clin. Invest. 45, 1826-1830 (1966).
18. Brock, DJ, Bolton AE, Monaghan JM. Prenatal diagnosis through maternal serum AFP measurement. Lancet 2, 293-294 (1973).
19. McLeod JF, Cooke NE. The vitamin D-binding protein, α-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J. Biol. Chem. 264, 21760-21769 (1989).
20. Lichenstein HS, Lyons DE, Wurfel MM et al. Afamin is a new member of the albumin, α-fetoprotein and vitamin D-binding protein gene family. J. Biol. Chem. 269, 18149-18154 (1994).
21. Breborowicz J. Microheterogeneity of human α-fetoprotein. Tumor Biol. 9, 3-14 (1988).
22. Taketa K. Multimodal application of lectin affinity electrophoresis of α-fetoprotein. Electrophoresis 19, 1774-1779 (1998).
23. Abelev GI. α-fetoprotein in association with malignant tumors. Adv. Cancer Res. 14, 295-357(1971).
24. Hasegawa H, Mukojima T, Hattori N, Sano R, Hirato T. Embryonal carcinoma and AFP with special reference to hepatoblastoma. Gann Monographs Cancer Res. 14, 129-131 (1973).
25. Ballas M. Yolk sac carcinoma of the ovary with AFP in serum and ascitic fluid demonstrated by immunomophoresis. Am. J. Clin. Pathol. 56, 511-513 (1972).
26. Wepsic HT. α-fetoprotein: its quantitation and relationship to neoplastic disease. In: α-fetoprotein Laboratory Procedures and Clinical Applications. Kirkpatrick AM, Nakamura RM (Eds) Masson Publ. New York, NY, USA, 115-129 (1981).
27. Miyazaki J, Endo Y, Oda T. Lectin affinities for α-fetoprotein in liver cirrhosis, hepatocellular carcinoma and metastatic liver tumor. Acta Hepatol. Jpn 22, 1559-1568 (1981).
28. Taketa K, Ichikawa E, Akamatsu K et al. Increased asialo αfetoprotein in patients with α-fetoprotein producing tumors: demonstration by affinity electrophoresis with erythroagglutinating phytohaemagglutinin of Phaseolus vulgaris lectin. Tumor Biol. 6, 533-544 (1985).
29. Aoyagi Y, Isemura M, Yosizawa Z et al. Fucosylation of serum αfetoprotein in patients with primary hepatocellular carcinoma. Biochim. Biophys. Acta 830, 217-223 (1985).
30. Kumada T, Nakano I, Takeda I, Kiriyama S, Sone Y, Hayashi K. Clinical utility of lens culivaris agglutinin-reactive AFP in small hepatocellular carcinoma: special reference to imaging diagnosis. J. Hepatol. 30, 125-130 (1999).
31. Smalley JR, Sarcione EJ. Synthesis of α-fetoprotein by immature rat uterus. Biochem. Biophys. Res. Commun. 92, 1429-1434, 19802930, (1997).
32. Taketa K. Characterization of sugar chain structures of human AFP by lectin affinity electrophoresis. Electrophoresis 19, 2595-2602 (1998).
33. Sarcione EJ, Smalley JR. Intracellular synthesis of α-fetoprotein and fibrinogen without secretion by Zajdela rat hepatoma cells. Cancer Res. 36, 3203-3205 (1976).
34. Smalley JR, Sarcione EJ. Synthesis of α-fetoprotein by immature rat uterus. Biochem. Biophys. Res. Commun. 92, 1429-1434 (1980).
35. Sarcione EJ, Zlotty M, Delluomo DS, Mizejewski GJ, Jacobson HI. Detection and measurement of α-fetoprotein in human breast cancer cytosol after treatment with 0.4 M potassium chloride. Cancer Res. 43, 37399-37441 (1983).
36. Mizejewski GJ, Brown-Buddle MM. Release of AFP from serine protease inhibitors in serum and tissue cytosols. In: Biological Activities of α-fetoprotein. Vol. II. Mizejewski GJ, Jacobson HI, (Eds). Boca Raton, FL: CRC Press 162-179 (1987).
37. Sarcione EJ, Biddle W. Elevated serum α-fetoprotcin levels in postmenopausal women with primary breast carcinoma. Dis. Markers 5, 75-79 (1987).
38. Sarcione EJ, Hart D. Biosynthesis of α-fetoprotein by MCF-7 human breast cancer cell. Int. J. Cancer 35, 315-318 (1985).
39. Biddle W, Sarcione EJ. Specific cytoplasmic AFP binding protein in MCF-7 human breast cancer cells and primary breast cancer tissue. Breast Cancer Res. Treat. 10, 279-286 (1987).
40. Esteban C, Terrier P, Frayssinet C, Uriel J. Expression of the α-fetoprotein gene in human breast cancer. Tumor Biol. 17, 299-305 (1996).
41. Benno RH, Williams TH. Evidence for intracellular localization of AFP in the developing rat brain. Brain Res. 142-146 (1978).
42. Moro R, Uriel J. Early localization of AFP in the developing nervous system of the chicken. Oncol. Develop. Biol. Med. 2, 391-399 (1981).
43. Uriel J, Trojan J, Dubauch P, Pineira. A Intracellular AFP and albumin in the developing nervous system of the baboon. Pathol. Biol. 30, 79-84 (1982).
44. Toran-Alleran CD. Coexistence of α-fetoprotein, albumin and transferring immunoreactiviry in neurons of the developing mouse brain. Nature 286, 733 (1980).
45. Trojan J, Uriel J. Immunocytochemical localization of AFP and serum albumin in ecto-, meso- and endodermal tissue derivatives of the developing rat. Oncodevelop. Biol. Med. 3, 13-22 (1982).
46. Uriel J. Poupon MF, Geuskens M. α-fetoprotein uptake by cloned cell lines derived from a nickel-induced rat rhabdomysosarcoma. Br. J. Cancer 48, 261-269 (1983).
47. Lorenzo HC, Geuskens M, Macho A et al. α-fetoprotein binding and uptake by primary cultures of human skeletal muscle. Tumor Biol. 17, 251-260 (1996).
48. Hajeri-Germond M, Trojan J, Uriel J, Hauw JJ. In vitro uptake of exogenous AFP by chicken dorsal root ganglia. Dev. Neurosci. 6, 11-15 (1983).
49. Uriel J, Trojan J, Moro R, Pineiro A. Intracellular uptake of α-fetoprotein: A marker of neural differentiation. Ann. NY Acad. Sci. 417, 321-329 (1983).
50. Villacampa MJ, Lampreave F, Calvo M, Naval J, Pineiro A, Uriel J. Incorporation of radiolabelled α-fetoprotein in the brain and other tissues of the developing rat. Dev. Brain Res. 12, 77-82 (1984).
51. Uriel J, Faivre-Bauman A, Trojan J, Doiret D. Immunocytochemical demonstration of α-fetoprotein uptake by primary cultures of fetal hemisphere cells from mouse brain. Neurosci. Lett. 27, 171-175 (1981).
52. 3H-arachidonic acid bound to AFP by autoradiography in rat rhabdomyosarcoma cells. J. Cell. Physiol. 128, 389-396 (1986).
53. Torres JM, Geuskens M, Uriel J. Reoeptor-mediated endocytosis and recycling of α-fetoprotein in human β-lymphoma and T-leukemia cells. Int. J. Cancer 47, 110-117 (1991).
54. Laborda J, Naval J, Allouche M et al. Specific uptake of α-fetoprotein by malignant human lymphoid cells. Int. J Cancer 40, 314-318 (1987).
55. Uriel, J, Naval J, Laborda J. α-fetoprotein mediated transfer of arachidonic acid into cultured cloned cells derived from a rat rhabdomyosarcoma. J Biol. Chem. 262, 2579-3585 (1987).
56. Hajere-Germond M, Naval J, Trojan J, Uriel J. The uptake of α-fetoprotein by C-1300 mouse neuroblastoma cells. Br. J. Cancer 51, 791-797 (1985).
57. Alava MA, Sturralde M, Lampreave F, Pineiro A. Specific uptake of α-fetoprotein and albumin by rat Morris 777 Hepatoma cells. Tumor Biol. 20, 52-64, 1999.
58. Uriel J, Failly-Crepin C, Villacampa MJ, Pineiro A, Geuskens M. Incorporation of AFP by the MCF-7 human breast cancer cell line. Tumor Biol. 5, 41-51 (1984).
59. Ockner RK, Weisigner RA, Gollan JL. Hepatic uptake of albumin-bound substances: the albumin receptor concept. Amer. J. Physiol. 245, 613-618 (1983).
60. Villacampa MJ, Moro R, Naval J, Failly-Crepin C, Lampreave F, Uriel J. α-fetoprotein receptors in a human breast cancer cell line. Biochem. Biophys. Res. Commun. 122, 1322-1327, (1984).
61. Suzuki Y, Zeng CQY, Alpert E. Isolation and characterization of a specific α-fetoprotein receptor on human monocytes. J. Clin. Invest. 90, 1530-1536 (1992).
62. Naval J, Villacampa MJ, Goguel AF, Uriel J. Cell type specific receptors for AFP in a mouse T-lymphoma cell line. Proc. Natl Acad. Sci. USA 82, 3301-3304 (1985).
63. Uriel J, Laborda J, Naval J, Geuskens M. α-fetoprotein receptors in malignant cells: an overview. In: Biological activities of α-fetoproteins. Mizejewski GJ, Jacobson HI (Eds). Boca Raton, CRC, 2, 103-117 (1989).
64. Torres JM, Carracq N, Uriel J. Membrane proteins from lymphoblastoid cells showing cross-affinity for α-fetoprotein and albumin. Isolation and characterization. Biochem. Biophys. Acta 1159, 60-66 (1992).
65. Moro R, Tamaoki T, Wegmann TG, Longnecker BM, Laderoute MP. Monoclonal antibodies directed against a widespread oncofetal antigen: the α-fetoprotein receptor. Tumor Biol. 14, 116-1130 (1993).
66. Laderoute MP. The characterization of a novel, widespread, PNA-reactive tumor associated antigen: the α-fetoprotein receptor/binding protein. PhD Thesis, Faculty of Graduate Studies and Research, University of Alberta, Canada, 1-256 (1991).
67. Laderoute MP, Wilans D, Wegmann T, Longenecker M. The identification, isolation and characterization of a 67-kilodalton, PNA-reactive autoantigen commonly express in human adenocarcinomas. Anticancer Res. 14, 1233-1246 (1994).
68. Kanevsky VY, Pozdnyakova LP, Aksenova OA, Severin SE, Karakov VY, Severin ES. Isolation and characterization of AFP-binding proteins from tumor and tumor and fetal tissues. Biochem. Mol. Biol. Internl 41, 1643-1151 (1997).
69. Esteban C, Trojan J, Macho A, Mishal Z, Lafarge-Frayssinet CH, Uriel J. Activation of an AFP/receptor pathway in human normal and malignant peripheral blood mononuclear cells. Leukemia 7, 1807-1816 (1993).
70. Uriel J, Torres JM, Anel A. Carrier protein-mediated enhancement of fatty acids transfer into human T-lymphocytes. Biochim. Biophys. Acta 1220, 231-240 (1994).
71. Torres JM, Anel A, Uriel J. AFP-mediated uptake of fatty acids by humanT-lymphocytes. J. Cell. Physiol. 150, 456-462 (1992).
72. Torres JM, Laborda J, Naval J, Darracq N, Mishal Z, Uriel J. Expression of α-fetoprotein receptors by human T-lymphocytes during blastic transformation. Mol. Immunol. 26, 851-857 (1989).
73. Geuskens M, Torres JM, Esteban C, Uriel J. Morphological characterization of the pathway of endocytosis and intracellular processing of transferring and α-fetoprotein in human T-lymphocytes stimulated with phytohemagglutinin (PHA). Eur. J. Cell. Biol. 418-427 (1989).
74. Kim EE, Deland FH, Goldenberg DM et al., Radio-immunodetection of cancer with radiolabeled antibodies to α-fetoprotein. Cancer Res. 40, 3008-3012 (1980).
75. Kaji, T, Ishu N, Nakamuia S, Tsukada Y, Nishi S, Hirai H. Localization of radioiodinated antibody to AFP in hepatoma transplanted in rats and a case report of AFP antibody treatment of a hepatoma patient. Cancer Res. 40, 3013-3015 (1980).
76. Amato R, Kim EE, Prow D, Andreopoulos D, Kasai LP. Radioimmunodetection of residual, recurrant, or metastatic germ cell tumors using technetium-99 antiAFP Fab fragment. J. Clin. Res. Clin. Oncol. 126, 161-167 (2000).
77. Uriel J, Villacampa MJ, Moro R, Naval J, Failly-Crepin C. Uptake of rediolabeled α-fetoprotein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. Cancer Res. 44, 5314-5319 (1984).
78. Moro R, Heuguerat C, Vercelli-Retta J, Fielitz W, Lopez JJ, Roca R. The use of radioiodinated α-fetoprotein for the sintigraphic detection of mouse mammary carcinomas. Nucl. Med Commun. 5, 5-12 (1984).
79. Line BR, Epstein MD, Mizejewski GJ. Medical potential of AFP as a tumor imaging agent. In: Biokgical Activities of α-fetoprotein. Mizejewski GJ, Jacobson HI (Eds) Florida, FL, USA 2, 139-147 (1989).
80. Moro R. The AFP receptor-A widespread oncofetal antigen. In: Biological Activities of α-fetoprotein. Mizejewski GJ, Jacobson HI (Eds) Florida, FL, USA, 119-127 (1989).
81. Line BR, Feustel PJ, Festin SM et al. Scintigraphic detection of breast cancer xenografts with Tc-99m natural and recombinant human α-fetoprotein. Cancer Biother. Radiopharm. 14, 485-494 (1999).
82. Mizejewski GJ, Allen RP. Immunotherapeutic suppression in transplantable solid tumors. Nature 250, 50-52 (1974).
83. Mizejewski GJ, Dillon WR. Immunobiologic studies in hepatoma-bearing mice passively immunized to α-fetoprotein. Arch. Immunol. Exptl. Therap. 27, 655-662(1979).
84. Alen RP, Mizejewski, GJ. Isolation and characterization of α-fetoprotein from the murine hepatoma BW7756. Biochem. Biophys. Acts. 491, 242 (1977).
85. Mizejewski GJ, Simon, R, Vonnegut M. Purification of α-fetoprotein from mouse amniotic fluid by gel-entrapped antibody filtration. J. Immuno. Meth. 31, 333 (1979).
86. Mizejewski GJ, Vonnegut M, Simon R. Estradiol affinity chromatography: application to purification of murine α-fetoprotein. J. Chrom. 202, 113 (1980).
87. Mizejewski GJ, Young SR, Allen RP. α-fetoprotein: effect of heterologous antiserum on hepatoma cells in vitro. J. Natl Cancer Inst. 54, 1361-1367 (1975).
88. Mizejewski GJ, Allen RP. α-fetoprotein: studies of tumor associated antigen cytotoxicity in mouse hepatoma BW7756. Clin. Immunol. Immunopathol. 11, 307-317 (1978).
89. Sheppard HW, Sell S, Trefts P, Bahn R. Effects of AFP on murine immune responses. I. Studies on mice. J. Immunol. 119, 91-97 (1977).
90. Gousev AI, Yazova AK. Termination of natural tolerance to α-fetoprotein in rats: Its effect on hepatoma growth and course of pregnancy. In: α-feto-protein. Massenyeff R (Eds) INSERM, Paris, France, 255 (1974).
91. Severin SE, Moskaleva EY, Shmyrev IT et al. AFP-mediated targeting of anticancer drugs to tumor cells in vitro. Biochem. Mol. Biol. Intl 37, 385-392, (1995).
92. Moskaleva EY, Posypanova GA, Shmyren IT et al. AFP-mediated targeting: a new strategy to overcome multi-drug resistance of tumor cells in vitro. Cell. Biol. Intl 21, 793-799 (1997).
93. Severin SE, Posypanova GA, Katukov VY et al. Antitumor activity of conjugates of the oncofetal protein AFP and phthalocyanines in vitro. Biochem. Mol. Biol. Intl 43, 1081-1089 (1997).
94. Severin SE, Moskaleva EY, Posypanova GA et al. In vivo antitumor activity of cytotoxic drugs conjugated with human AFP. Tumor Targeting 2, 299-306, (1996).
95. Sotnichenko AI, Severin SE, Posypanova GA et al. Water soluble 2,3,7,8-tetrachlorodibenzo-p-dioxin complex with human AFP: properties, toxicity in vivo and antitumor activity in vivo. FEBS Lett. 450, 49-51 (1999).
96. Lutsenko SV, Feldmen NB, Finakova GV et al. Antitumor activity of α-fetoprotein and epidermal growth factor conjugates in vitro and in vivo. Tumor Biol. 21, 367-374 (2000).
97. Savitsky AA, Gukasova NV, Severin SE et al. Cytotoxic action of conjugates of α-fetoprotein and epidermal growth factor with photoheme, chlorines and pthalocyanines. Biochem. 65, 732-736 (2000).
98. Beluskina NN, Severin SE. Molecular mechanisms of apoptosis pathology. Arkhiv. Pathologü. 63, 51-60 (2001).
99. Severin SE, Posypanova GA, Sotnichenko AI, Severin ES, Petrov RV. Antitumor activity of a conjugate of endiyne antibiotic esperamicin-A(b) with human α-fetoprotein. Doklady Akademii Nauk 366, 561-564 (1999).
100. Feldman NB, Kiselev SM, Severin SE. Antitumor activity of AFP conjugate with doxorubicin in vitro and in vivo. Biochem. 65, 967-971 (2000).
101. Gershwin NME, Castles JJ, Makishima R. Accelerated plasmacytoma formation in mice treated with α-fetoprotein. J Natl Cancer Inst. 64, 145-149 (1980).
102. Mizejewski GJ. Immunologic prospects for mammalian α-fetoprotein. Clin. Immunol. Newsletter 2, 37-39 (1981).
103. Gershwin ME et al. The influence of α-fetoprotein on Moloney sarcoma virus oncogenesis: evidence for generation of antigen nonspecific suppressor T. cells. J. Immunol. 121, 2292-2298 (1978).
104. Wang XW, Xie H. Stimulation of tumor cell growth by α-fetoprotein. Intl J. Cancer 75, 596-599 (1998).
105. Jacobson HI, Bennett JA, Mizejewski GJ. Inhibition of estrogen-dependent breast cancer growth by a reaction product of α-fetoprotein and estradiol. Cancer Res. 50, 415-420 (1990).
106. Butterstein GM, Mizejewski GJ. α-fetoprotein inhibits frog metamorphosis: implications for protein motif conservation. Comp. Biochem. Physiol. 124A, 39-45 (1999).
107. Mizejewski GJ, Warner AS. α-fetoprotein can regulate growth in the immature and adult hyophysectomized mouse uterus. J. Reprod. Fertil. 85, 177-185 (1988).
108. Mizejewski GJ, Keenan, JF, Setty RP. Separation of the estrogen-activated growth regulatory forms of α-fetoprotein in mouse amniotic fluid. Biol. Reprod. 42, 887-898 (1990).
109. Dudich E, Semenkova L, Gorbatova E et al. Growth-regulative activity of human α-fetoprotein for different types of tumor and normal cells. Tumor Biol. 19, 30-40 (1998).
110. Mizejewski GJ, Vonnegut M, Jacobson HI. Studies of the intrinsic anti-uterotropic activity of murine α-fetoprotein. Tumor Biol. 7, 19-28 (1986).
111. Mizejewski GJ, Vonnegut M, Jacobson HI. Estradiol-activated α-fetoprotein suppresses the uterotropic response to estrogens. Proc. Soc. Natl Acad. Sci USA 80, 2733-2737 (1983).
112. Jacobson HI, Mizejewski GJ. Effect of estradiol-activated α-fetoprotein on the growth of rat mammary tumors. Internatl Assoc. Breast Tumor Res. 34 (1983).
113. Mizejewski GJ, Jacobson HI. α-fetoprotein is a dual regulator of growth in estrogen responsive tissues. In: Biological Activities of α-Fetoprotein. Mizejewski GJ, Jacobson HI (Eds). CRC Press, Boca Raton, Florida, FL, USA, 1. 71-82 (1987).
114. Leffert HI, Sell S. α-fetoprotein biosynthesis during the growth cycle of differentiated fetal rat hepatocytes in primary monolayer culture. J. Cell. Biol. 61, 823-829 (1974).
115. Toder V, Bland, M, old-Gefter L, Nebel J. The effect of α-fetoprotein on the growth of placental cells in vitro. Placenta 4, 79-86 (1983).
116. Hamel S, Hoskin DW, Hooper DC, Murgita RA. Phenotype and function of bone marrow-derived T and non-T cells activated in vitro by α-fetoprotein. In: Biological Activities of α-fetoprotein. Mizejewski GJ, Jacobson HI (Eds). CRC Press, FL, USA, 1, 167-177 (1987).
117. Leal JA, May JV, Keel BA. Human α-fetoprotein enhances epidermal growth factor proliferation activity upon porcine granulosal cells in monolayer culture. Endocrinology 126, 669-671 (1980).
118. Keel BA, Eddy KB, Cho S, May JV. Synergistic action of purified α-fetoprotein and growth factors on the proliferation of porcine granulosa cells in monolayer culture. Endocrinologv 129, 217-225 (1991).
119. Bennett JA, Mizejewski GJ, Allen SHG, Zhu SJ, Jacobson HI. Transformation of apha-fetoprotein to a negative regulator of estrogen-dependent growth by ligands of the steroid/thyroid hormone receptor superfamily. 18th International Congress, J. Cancer Res. Clin. Oncol. 34, 244 (1993).
120. Goncharova O, Dudich F, Semenkova L, Gorbatova E, Dudich I. Synergy of α-fetoprotein and estradiol in suppression of tumor cell growth. Tumor Biol. 20, 42-44 (1999).
121. Semenkova LN, Dudich EI, Dudich IV, Shingarova LN and Korobko VG. α-fetoprotein as a TNF-resistance factor for human hepatocarcinoma cell line HepG2. Tumor Biol. 18, 30-40, (1997).
122. Semenkova LN, Dudich EI, Dudich IV. α-fetoprotein-induced apoptosis of human hepatoma cells. Tumor Biol. 19, 261-274 (1998).
123. 2+ and tyrosine-kinase independent pathways and do not require protein and RNA synthesis. Tumor Biol. 19 (S2), 26 (1998).
124. Semenkova LN, Dudich EI, Khromikh LM, Gorbatova EA. Abrogation of α-fetoprotein-induced apoptosis in tumor cells by endogenous exogenous IL-2. Eur. Cytokine Network 9, 448 (1998).
125. Dudich I, Dudich E, Semenkova LN, Gorbatova EA, Shingarova L, Korobko V. Comparative study of the biological activity of TNF-R55 and TNF-R75-selective TNF-α mutants using various types of tumor cell lines. Eur. Cytokine Network 9, 489 (1998).
126. Dudich E, Seminkova L, Gorbatova E, Dudich I, Shingarova L, Korobko V. α-fetoprotein-induced apoptosis in tumor cells is differentially modulated by RNFR55 and TNF-R75-dependent signaling. Eur. Cytokine Network 9, 488, (1988).
127. Dudich EI, Seminkova LN, Dudich IV et al. α-fetoprotein causes apoptosis in tumor cells via activation of caspase-3 and bypasses fas-and TNF-R1-dependent signaling. Eur. J. Biochem. 266, 750-761 (1999).
128. Dudich E, Semenkova L, Gorbatova E, Dudich I. Targeting modulation of the TNF-induced apoptosis in tumor cells by human α-fetoprotein: new approach for anticancer therapy. J. Interferon Cytokine Res. 19, 1140 (1999).
129. Festin, SM, Bennett JA, Fletcher PW, Jacobson HI, Shaye DD, Andersen TT. The recombinant third domain of human α-fetoprotein retains the anti-estrotrophic activity found in the full length molecule. Biochem. Biophys Acta 24789, 307-314 (1999).
130. Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy J. α-fetoprotein derived synthetic peptides: Assay of an estrogen-modifying regulatory segment. Mol. Cell. Endocrinol. 118, 15-23 (1996).
131. Vakharia D, Mizejewski GJ. Human α-fetoprotein peptides bind estrogen receptor and estradiol and suppress breast cancer.
132. Bennett JA, Zhu S, Pogano-Mirachi A, Kellom TA, Jacobson HI. AFP derived from a human hepatoma, prevents growth of estrogen-dependent human breast cancer xenografts. Clin. Cancer Res. 4, 2877-2884 (1998).
133. Deutsch HF, Taniguchi N, Evenson MA. Isolation and properties of human AFP from Hep G2 cell cultures. Tumor Biol. 211, 267-277(2000).
134. Mizejewski GJ, Jacobson HI. Stability of the complex formation between estrogen and α-fetoprotein. Fed. Proceed. 41, 1495 (1982).
135. Hsourigui M, Thabie N, Martin ME, Benassayag C, Nunez EA. In vivo transient rise in plasma free fatty acids alters the functional properties of α-fetoprotein. Biochim. Biophys. Acta 1125, 157-165 (1992).
136. Mizejewski GJ. An apparent dimerization motif in the third domain of α-fetoprotein: molecular mimicry of the steroid/thyroid nuclear receptor superfamily. Bioessays 15, 427-432(1993).
137. Mizejewski GJ. α-fetoprotein binding proteins: Implications for transmembrane passage and subcellular localization. Life Sciences 56, 1-9 (1994).
138. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Pros. Soc. Exptl Biol Med. 222, 124-138 (1999).
139. Seal W, Hanstein B, Brown M, Moore DD. Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol. Endocrinol. 12, 1551-1557(1998).
140. Resnick EM, Schreihofer DA, Periasamy A, Shupnik, MA. Truncated estrogen receptor product-1 suppresses estrogen receptor transactivation by dimerization with estrogen receptors α and β. J. Biol. Chem. 275, 7158-7166 (2000).
141. Chou JY, Savirz AJ. AFP synthesis in transformed fetal rat liver cells. Biochem. Biophys. Res. Commun. 135, 844-851 (1986).
142. Chou JY, Ito F, Evans G, Chiu FJ, Feldman M. α-fetoprotein biosynthesis and hepatocellular differentiation. Biochem. Biophys. Res. Commun. 108, 15241-15250 (1982).
143. Lemire JM, Fausto N. Multiple α-fetoprotein RNAs in adult rat liver cell type-specific expression and differential regulation. Cancer Res. 51, 4656-4664 (1991).
144. Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. Semin. Cancer Biol. 5, 381-389 (1994).
145. Lobenhofer EK, Huper G, Inglehart JD, Marks JR. Inhibition of Mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell. Growth Diff. 11, 99-110 (2000).
146. Endoh H, Sasaki H, Maruyama K et al. Rapid activation of MAPK by estrogen in a bone cell line. Biochem. Biophys Res. Commun. 235, 99-102 (1997).
147. Matsushime H, Quelle DE, Shurtleff SA et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, 2066-2076(1994).
148. Devi LA, Heterodimerization of G-protein coupled receptors: pharmacology, signaling and trafficking. Trend Pharmacol. Sci. 22, 532-537 (2001).
149. Milligan G, White JH. Protein-protein interactions at G-protein coupled receptors. Trends Pharmacol. Sci. 22, 513-518 (2000).
150. Marinissen MJ, Gutkind JS, G-protein coupled receptors and signaling networks: emerging paradigms. Trends Pharm Sci. 22, 368-376 (2001).
151. McLatchie LM. Ramps regulate the transport and ligand specificity of the calcitonin receptor-like receptor. Nature 393, 333-339 (1998).
152. Foordi SM, Marshall FH. Ramps, accessory proteins for seven transmembrane domain receptors. Trends Pharm. Sci. 20, 184-187 (1999).
153. Lefkowitz RJ. The superfamily of heptahelical receptors. Nature Cell. Biol. 2, E133-E136 (2000).
154. Katragadda M, Chapra A, Bennett M et al. Structures of the transmembrane helices of the G-protein coupled receptor, rhodopsin. J. Rep. Res. 58, 79-89 (2001).
155. Bochaert J, Pin JP. Molecular tinkering of G-protein coupled receptors: an evolutionary success. EMBO 18, 1723-1729 (1999).
156. Banemann M, Hosey M. G-protein coupled receptor kinases as modulators of G-protein signaling. J. Physiology 517, 5-23 (1999)
157. Freedman NJ, Lefkowitz RJ. Desensitiziton of G-protein coupled receptors. Rec. Progr. Cancer Res. 51, 319-351 (1996).
158. Clark RB, Knoll BJ, Barber R. Partial agonists and G-protein coupled receptor desensitization. Trends Pharmacol. Sci. 20, 279-286 (1999).
159. McNiven MA, Cao H, Pitts KR, Yoon Y. The dynamin family of mechanoenzymes: Pinching in new places. Trends Biol. Sci. 25, 115-120 (2000).
160. Oakley RH, Laporte SA, Holt JA, Barak S, Caron MG. Association of B-arrestin with G Protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem 274, 32248-32257 (1999).
161. Krupnick JG, Goodman OB, Keen JH, Benovic JL. Arrestin/Clathrin interaction localization of the clathrin binding domain of nonvisual arrestins to the carboxyl terminus. J. Biol. Chem. 272, 15011-15016 (1997).
162. Freissmuth M, Waldheer M, Bofill-Cardona E, Nanoff C. G-protein antagonists. Trends Pharmacol. Sci. 20, 237-244 (1999).
163. 2-adrenergic receptor. J Biol. Chem. 276, 24433-24436 (2001).
164. Powell KJ, Ma W. Sutak M. et al. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. J. Pharmacol. 131, 875-884 (2000).
165. Bruns CJ, Salarzano CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel trytosine kinase inhibitor. Cancer Res. 60, 2925-2935 (2000).
166. Bockaert J, Pin JP. Molecular tinkering of G-protein coupled receptors: an evolutionary success. EMBO J. 18, 1723-1729 (1999).
167. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G-protein coupled receptors: Implications of the high resultion structure of rhodopin for structure function analysis of receptors. Mol. Pharmacol. 60, 1-19 (2001).
168. Menon ST, Han M, Sakmar TP. Rhodopsin: structural basis of molecular physiology. Physiol Rev. 81, 1659-1681 (2001).
169. Tokita K, Katsuno T, Hocart SJ et al. Molecular basis for selectiority of high affinity peptide antagonist for the gastrin-releasing peptide receptor. J Biol Chem. 276, 36652-36663 (2001).
170. 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276, 29171-29177 (2001).
171. Ghanouni P Grycznski Z, Steenhuis JJ et al. Functionally different agonists induce distinct conformations in the G-protein coupling domain. J. Biol. Chem. 276, 24433-24436 (2001).
172. Bloch W, Fan Y, Han J et al. Disruption of cytoskeletal integrity impairs Gi-mediated signaling due to displacement of Gi proteins. J. Cell. Biol. 154, 753-761 (2001).
173. Lin CT, Wu HC, Cheng HF et al. Identification of β-subunit of GTP-Binding regulatory protein in mitotic spindle. Lab. Invest. 67, 770-778 (1992).
174. Druey W, Blumer KJ, Kang VM, Kehri JH. Inhibition of G-protein-mediated MAPK activation by a new mammalian gene family. Nature 379, 742-746 (1996).
175. Reif K, Cyster JG. RGS molecule expression in mutine β-lymphocytes and ability to downregulate chemotoxis to lymphoic chemokines. J. Immunol. 164, 4720-4729 (2000).
176. Berman DM, Gilman AG. Mammalian RGS proteins: barbarians at the gate. J Biol. Chem. 273, 1269-1272 (1998).
177. Zhong H, Neubig RR. Regulator of G protein signaling proteins: novel multifunctional drug targets. J. Pharmacol. Exptl Therapy 297, 837-845 (2001).
178. 1γ2-induced inositol phosphate production, mitogen activated protein kinase activation and Akt activation. J. Biol. Chem. 276, 24293-24300 (2001).
179. Helper JR. Emerging roles for RGS proteins in cell signaling. Trends Pharmacol. Sci. 20, 376-382 (1999).
180. αo and Gαq signaling in neurons require GB5 subuit for function. Curr. Biol. 11, 222-231 (2001).
181. q and a patent inhibitor of signaling by GTPase-deficient forms of Gαq and Gα11. Mol. Pharmacol. 58, 719-728 (2000).
182. Gelb MH. Protein prenylation, et cetera: signal transduction in two dimensions. Science 275, 1750-1751 (1997).
183. Gotoh T, Tian Y, Feig LA. Prenylation of target GTPases contributes to signaling specificity of Ras-Guanidine nucleotide exchange factors. J Biol. Chem. 276, 38029-38035 (2000).
184. Tu Y, Woodson J, Ross EM. Binding of regulator of G-protein signaling (RGS) proteins to phospholipid bilayers. J. Biol. Chem. 276, 20160-20166 (2001).
185. Inglese J, Koch WJ, Caron MG, Lefkowitz RJ. Isoprenylation in regulation of signal transduction by G-protein coupled receptor kinases. Nature 359, 147-150 (1992).
186. 1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation and sequestiation. J. Biol. Chem. 276, 38139-38146 (2001).
187. Fenton JW, Shen GX, Minnear FD et al., Statin drugs and dietary isoprenoids as antithrombotic agents. Hematol. Oneal. Clin. N. Am. 14, 483-489 (2000).
188. Fenton JW, Shen GX. Statins as cellular thromatics. Haemostasis 29, 166-169 (1999).
189. Ruiz-Gutierrez V, Moreno R, Moreda W, Copado MA. Rodriguez-Burgos A. Detection of squalene in α-fetoprotein and fetal serum albumin from bovine. J. Protein Chem. 20, 19-23 (2001).
190. Chen H, Egan Jo, Chiu JF. Regulation and activities of α-fetoprotein. Crit. Rev. Eukary. Gene Exp. 7, 11-41 (1997).
191. Lazarevich NL. Molecular mechanisms of α-fetoprotein gene expression. Biochim 65, 117-133 (2000).
192. Matsumura M, Shiratori Y, Niwa Y, Tanaka T, Ogura K. Presence of α-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma. Hepatol. 31, 332-339 (1999).
193. Ido A, Ishikawa H, Wakata K, Eguchi K. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of the AFP gene promoter. Cancer Res. 55, 3105-3109 (1995).
194. Ishikawa H, Nakata K, Nawatari F, Ueki T. Utilization of variant-type of human AFP promoter in gene therapy targeting for hepatocellular carcinoma. Gene Therapy 6, 465-470 (1999).
195. Wang XW, Xie H. Growth inhibition of human liver cancer cells by α-fetoprotein antisense strategy. Cell. Dev. Biol. 35, 118-119 (1999).
196. Vollmer CM, Eilber FC, Butterfield LH, Ribas A. Economou JS. α-fetoprotein-specific genetic immunotherapy for heptocellular carcinoma. Cancer Res. 59, 3064-3067 (1999).
197. Butterfield LH, Koh A, Meng W, Vollmer CM, Economou JS. Generation of human t-cell responses to an HLA-A.2. 1-restricted peptide epitope derived from α-fetoprotein. Cancer Res. 59, 3134-3142 (1999).
198. Wilson SM, Butterfield LH, Ribas A et al. Fine specificity analysis of an HLA-A2.1 restricted immunodominant T-cell eptitope derived from human α-fetoprotein. Mol. Immunol. 37, 943-950 (2000).
199. Butterfield LH, Wilson SM, Koh A et al. T-cell responses to HLA-A-0201 restricted peptides derived from human α-fetoprotein J. Immunol. 166, 5300-5308 (2001).
200. Chou WC, Liao KW, Lo YC, Jiang SY, Yeh MY, Roffler SR. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotech. Bioengineer 65, 160-169 (1999).
201. Wan YJ, Pan T, Wang L, Locker J, Wu TC. T-cis retinoic acid is more effective than all-trans-retinoic acid in upregulating expression of the AFP gene. J Mol. Endocrinol. 14, 101-108 (1995).
202. Bois-Joyeux B, Denissenko M, Thomassin H et al. The c-jun proto-oncogene downregulates the rat AFP promoter in HepG2 hepatoma cells without binding to DNA. J. Biol. Chem. 270, 10204-10211, (1995).
203. Thomassin H, Bois-Joyeux B, Delille R, Ikonomova R, Danan JL. Coup-transcription factor, hepatocyte nuclear factor-3 and CCAAT/enhancer binding protein control the far-upstream enhancer of the rat α-fetoprotein gene. DNA Cell Biol. 15, 1063-1074 (1996).
204. Ido A, Uto H, Moriuchi A, Nagata K, Onago Y. Gene therapy targeting for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to human α-fetoprotein promoter. Cancer Res. 61, 3016-3021 (2001).
205. Galarneu L, Par JF, Allard D et al. The AFP locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol. Cell. Biol. 16, 3853-3865 (1996).
206. Richardson BE, Hulka BS, David Peck JL et al. Levels of maternal serum α-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am. J Epidemiol. 148, 719-727 (1998).
207. Melbye M, Wohlfahrt J, Lei U et al. α-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J. Natl Cancer Inst. 92, 1001-1005 (2000).
208. Janerich DT. Familial associations between birth defects and cancer. Am. J. Epidemol. 102, 456-457 (1975).
209. Jacobson HI, Janerich DT. Pregnancy altered breast cancer risK: mediated by maternal serum AFP? In: Biological Activities of AFP Mizejewski GJ, Jacobson HI (Eds). CRC Press, FL, USA, 2, 93-100 (1989).
210. Jaccobson HI, Thompson WD, Janerich DT. Multiple births and maternal risk of breast cancer. Am. J. Epidem. 129, 65-873 (1989).
211. Thompson WD, Jacobson HI, Negrini B. Hypertension and risk of breast cancer. J. Natl Cancer Inst. 81, 1571-1574 (1989).
212. Eisle L, Mesfin F, Bennett J, MacColl R, Mizejewski G. Studies on a growth-inhibitory peptide derived from AFP and some analogs. J. Peptide Res. 57, 29-38 (2001).
213. Browder T, Folkman, J, Pirie-Sheperd S. The hemostatic system as a regulator of angiogenesis: a review. J. Bio. Chem. 275, 1521-1524(2000).
214. Wen W, Moses MA, Wiederschain D, Arbizer JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 59, 6052-6056 (1999).
215. Weissbach L, Bussar-Maatz R, Mann K. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Europ. Urol. 32(1), 16-22 (1997).
216. Kanazawa R, Kogure K, Kominami S, Kobayashi S, Teramoto A. Ependymal cyst producing α-fetoprotein. Case report. J. Neurosurgery 93(4), 682-685 (2000).
217. Nakashima H, Nagafuchi K, Satoh H et al. Hepatoid adenocarcinoma of the gallbladder. J. Hepato-Biliary-Pancreatic Surg. 7(2), 226-230 (2000).
218. Eriguchi N, Aoyagi S, Hara M et al. Large acinar cell carcinoma of the pancreas in a patient with elevated serum AFP level. J Hepato-Biliary-Pancreatic Surg. 7(2), 222-225 (2000).
219. Amemiya H, Kono K, Mori Y et al. High frequency of c-Met expression in gastric cancers producing α-fetoprotein. Oncology 59(2), 145-151 (2000).
220. Kure M, Mizokami Y, Shiraishi T et al. A case of clear cell carcinoma of the hepatic bile duct with production of α-fetoprotein (AFP). Nippon Shokakibyo Gakkai Zasshi-Japanese J. Gastroenterol. 97(7), 936-940 (2000).
221. Mouko A. Moukassa D, Leroy X et al. Early isosexual precocious pseudopuberty revealing a juvenile granulose cell tumor in a 3-year-old Congolese girl. Ann. de Pathologie 20(3), 245-248 (2000).
222. MacDonald N, Chudley AE. Fetal hepatic haemangioendothelioma: a new association with elevated maternal serum α-fetorprotein. Prenatal Diagnosis 20(5), 432-435 (2000).
223. Kitano Y. Ruchelli E. Weiner S, Adzick NS. Hepatic mesenchymal hamartoma associated with mesenchymall stem villous hyperplasia of the placenta. Fetal Diagn. Ther. 15(3), 134-138 (2000).
224. Shintaku M. Kariya M. Shime H, Ishikura H. Adenocarcinoma of the uterine cervix with choriocarciomatous and hepatoid differentiation: report of a case. Internatl J. Gynecological Pathol. 19(2), 174-178 (2000).
225. Tsujikawa T, Tsukamoto H, Itoh A et al. Meningitis carcinomatosa originating from an α fetoprotein-producing gastric cancer. Internal Med. 39(3), 223-227 (2000).
226. Giustozzi G, Coracci G, Bufalari A et al. Hepatoid Carcinoma of the stomach: is it still an unusual anatomo-clinical entity? Six cases-report. J. Experimental Clin. Cancer Res. 18(4), 571-573 (1999).
227. Rebischung C. Pautier P, Morice P, Lhomme C. Duvillard P α-fetoprotein production by a malignant mixed Mullerian tumor of the ovary. Gynecologic Oncol. 77(1), 203-205 (2000).
228. Schneider DT, Calaminus G, Reinhard H et al. Primary-mediastinal germ cell tumors in children and adolescents: results of the German co-operative protocols. J. Clin. Oncol. 18(4), 832-839 (2000).
229. Shimakawa T. Ogawa K. Naritaka Y et al. α-fetoprotein producing Barrett's esophageal adenocarcinoma: a case report. Anticancer Research 19(5C), 4369-4373 (1999).
230. Heny MA. Bouvier R. Ranchere D et al. Case report: a preterm infant with an extradural myxopapillary ependymoma component of a teratoma and high levels of α-fetoprotein. Pediatric Hematol. Oncol. 15(5), 437-441 (1998).
231. Kise H, Kanda H, Hayashi N, Arima K, Yanagawa M, Kawamura J. α-fetoprotein producing urachal tumor. J. Urol. 163 (2), 547 (2000).
232. Sata W, Kato K, Takahashi M, Yamada D, Midorigawa S, Watanabe T. Nozawa Y. Abe M. Kitsunai H. Case of α-fetoprotein-producing cancer of the ascending colon with invasion of the superior mesenteric vein and portal system. Nippon Naika Gakkai Zasshi. J. Japanese Soc. Inter. Med. 88(11), 2242-2244, (1999).
233. Tsuchida Y. Ikeda H. Suzuki N et al. A case of well-differentiated, fetal-type hepatoblastoma with very low serum α-fetoprotein. J. Pediatric Surg. 34(12), 1762-1764 (1999).
234. Tanno S. Obara T. Fujii T et al. α-fetoprotein-producing adenocarcinoma of the pancreas presenting focal hepatoid differentiation. International J. Pancreatology 26(1), 43-47 (1999).
235. Nishioka H, Ito H, Haraoka J, Akada K. Immature teratoma originating from the pituitary gland: case report. Neurosurgery 44(3), 644-647(1999).
236. Ushio Y, Kochi M, Kuratsu J, Itoyama Y, Marubayashi T. Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases. J Neurosurgery 90(1), (1999).
237. Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical stud of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma and cholangiocarcinoma with α-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen and cytokeratins 18 and 19. Pathol. International 49 (4), 310-317 (1999).
238. Kato T, Inoue K, Nishiyama N et al. Resected case of synchronous double cancer of lung and ovarium. Kyobu Geka - Japanese J. Thoracic Surg. 52(5), 416-418 (1999).
239. Hirota F, Hosaka K, Funahashi K et al. Effective treatment of AFP-producing lung cancer with UFT. Japanese J. Cancer Chemo. 26(3), 381-394 (1999).
240. St Laurent M, Esterl RM Jr, Halff GA, Speeg KV. Gallbladder carcinoma producing α-fetoprotein. J. Clin. Gastroenterol. 28(2), 155-158 (1999).
241. Geissler M, Mohr L, Weth R. Immunotherapy directed against α-fetoprotein results in autoimmune liver disease during liver regeneration in mice. Gastroenterology 121, 931-939 (2001).
242. Dudich I, Tokhtamysheva N, Semenkova L, Dudich E, Hellman J, Korpela T. Isolation and structural and functional characterization of the two stable peptide fragments of human α-fetoprotein. Biochemistry 38, 10406-10414, (1999).
243. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9, 459-470, (2002).
244. Mizejewski GJ Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction. Expert Opin. Investig Drugs 10, 1063-1073 (2001).
245. Eisele LE, Mesfin FB, Bennett JA et al. Studies on analogs of a peptide derived from α-fetoprotein having antigrowth properties. J. Peptide Res. 57, 539-546 (2001).
246. MacColl R, Eisele LE, Stack RF et al. Interrelationships among secondary structure and metal ion binding for a chemically synthesized 34-amino acid peptide derived from α-fetoprotein.